Form 4: Alkermes Director Frank Anders Wilson Reports Acquisition of Stock Options and Restricted Stock Units

Alkermes plc Director Frank Anders Wilson has reported the acquisition of 13,474 non-qualified stock options and 6,142 restricted stock units on May 21, 2025.

Summary

• Frank Anders Wilson, a Director of Alkermes plc (ALKS), acquired new equity awards as reported in a Form 4 filing.
• On May 21, 2025, Mr. Wilson was granted 13,474 non-qualified stock options.
• These stock options have an exercise price of $30.53 per share.
• The stock options will vest and become exercisable in full on May 21, 2026, and are set to expire on May 21, 2035.
• Additionally, Mr. Wilson received 6,142 Restricted Stock Unit (RSU) awards on May 21, 2025.
• Each RSU represents a contingent right to receive one ordinary share of Alkermes plc.
• The RSU awards will vest in full on May 21, 2026.
• Following these transactions, Mr. Wilson directly beneficially owns 13,474 non-qualified stock options and 6,142 restricted stock units.

Sentiment

Score: 7

Explanation: The filing indicates a routine equity compensation grant to a director, which is generally a positive sign of continued alignment between management and shareholder interests. It's not a major market-moving event but reflects standard corporate governance and compensation practices.

Positives

• Director Frank Anders Wilson received new equity awards, which typically aligns his long-term interests with those of the company's shareholders.
• The grants include 13,474 non-qualified stock options and 6,142 restricted stock units, indicating continued compensation and retention of a key director.

Future Outlook

The vesting schedules for the stock options and restricted stock units indicate that these awards will become exercisable and vest on May 21, 2026, aligning the director's long-term incentives with the company's future performance and shareholder value creation.

Industry Context

This Form 4 filing reflects a routine equity compensation grant to a director in the biotechnology/pharmaceutical industry, a common practice to align executive and director interests with long-term shareholder value. Such grants are standard in industries where long-term research and development cycles and intellectual property development are key value drivers, incentivizing sustained commitment.

Comparison to Industry Standards

• The grant of stock options and restricted stock units to a director is a standard practice in the biotechnology and pharmaceutical sectors, comparable to compensation structures seen at companies like Biogen Inc., Gilead Sciences, Inc., or Amgen Inc.
• These types of equity awards are frequently used by industry peers to incentivize and retain key personnel, aligning their financial interests with the company's long-term performance.
• The specific number of units and exercise price would typically be benchmarked against peer group compensation data, though such detailed comparison data is not provided in this Form 4.

Stakeholder Impact

• Shareholders: The equity awards align the director's financial interests with long-term shareholder value creation, as the value of the awards is tied to the company's stock performance.
• Employees: No direct impact on general employees is indicated by this specific insider transaction report.

Next Steps

• The non-qualified stock options and restricted stock units granted will vest on May 21, 2026.
• The non-qualified stock options will expire on May 21, 2035.

Key Dates

Recommendation

Keywords

Alkermes plc, ALKS, Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Equity Awards, Director Compensation, Beneficial Ownership